← All drugs
Drug · FAERS side-effect profile with label screen

Fish Oil side effects: what 89,854 FDA adverse event reports show

Fish Oil · Omegaven · 1,178 reaction terms · 434,938 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Omegaven

openFDA label

Who reports

89,854 reports · 49% serious · 4,529 with death outcome · 62% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). Limitations of Use: • Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients .

FDA label, Indications and Usage

What it is

Omegaven (fish oil triglycerides) is a sterile, nonpyrogenic, white, homogenous emulsion for intravenous infusion as a supply of calories in patients with PNAC.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Lab value / disease marker 7Not in label — unassessed 33
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,138 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Subcutaneous drug absorption impaired13879.1
65.2–95.9ROR 79.2 · calibrated p 8e-7 ✓
58.6 EB05 50.8 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=138 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Hypocholesterolaemia7777.7
60.0–100.7ROR 77.8 · calibrated p 1e-6 ✓
57.5 EB05 47.5 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=76 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
C-reactive protein22576.8
66.1–89.4ROR 77.0 · calibrated p 9e-7 ✓
57.5 EB05 51.5 · IC025 +5.5
3/3 methods agree
Lab value / disease markerserious n=225 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Deep vein thrombosis postoperative46973.3
66.0–81.3ROR 73.6 · calibrated p 1e-6 ✓
55.6 EB05 51.5 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious n=469 · ♀ 100% (drug 62%)not reported in cached trials
Lupus vulgaris19746.2
39.6–53.8ROR 46.3 · calibrated p 2e-5 ✓
38.5 EB05 34.2 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=197 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody10844.9
36.6–55.2ROR 45.0 · calibrated p 3e-5 ✓
37.5 EB05 31.9 · IC025 +4.7
3/3 methods agree
Lab value / disease markerserious n=108 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Swollen joint count increased47141.4
37.5–45.6ROR 41.6 · calibrated p 4e-5 ✓
35.2 EB05 32.6 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious n=471 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Facet joint syndrome47541.3
37.4–45.5ROR 41.5 · calibrated p 4e-5 ✓
35.1 EB05 32.5 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=475 · ♀ 100% (drug 62%) · 93% cliniciannot reported in cached trials
X-ray abnormal25538.8
34.0–44.3ROR 38.9 · calibrated p 7e-5 ✓
33.2 EB05 30.0 · IC025 +4.8
3/3 methods agree
Lab value / disease markerserious n=255 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Peripheral venous disease52735.4
32.3–38.8ROR 35.6 · calibrated p 1e-4 ✓
30.7 EB05 28.6 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=522 · ♀ 100% (drug 62%) · 93% cliniciannot reported in cached trials
Adjustment disorder with depressed mood26435.1
30.8–39.9ROR 35.2 · calibrated p 1e-4 ✓
30.5 EB05 27.5 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=259 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Dislocation of vertebra28333.9
29.9–38.4ROR 34.0 · calibrated p 1e-4 ✓
29.6 EB05 26.8 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=283 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Rheumatic fever53232.3
29.5–35.3ROR 32.4 · calibrated p 2e-4 ✓
28.4 EB05 26.4 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=532 · ♀ 100% (drug 62%) · 95% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody positive81730.2
28.1–32.5ROR 30.5 · calibrated p 2e-4 ✓
26.8 EB05 25.3 · IC025 +4.6
3/3 methods agree
Lab value / disease markerserious PRR 31.8 · ♀ 100% (drug 62%) · 96% cliniciannot reported in cached trials
Duodenal ulcer perforation84130.1
28.0–32.3ROR 30.4 · calibrated p 2e-4 ✓
26.7 EB05 25.2 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious PRR 31.5 · ♀ 100% (drug 62%) · 93% cliniciannot reported in cached trials
Rheumatoid factor positive63929.0
26.7–31.4ROR 29.2 · calibrated p 3e-4 ✓
25.8 EB05 24.2 · IC025 +4.5
3/3 methods agree
Lab value / disease markerserious n=639 · ♀ 100% (drug 62%) · 95% cliniciannot reported in cached trials
Muscle injury89428.4
26.5–30.5ROR 28.7 · calibrated p 3e-4 ✓
25.4 EB05 24.0 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious PRR 32.2 · ♀ 97% (drug 62%) · 92% cliniciannot reported in cached trials
Sleep disorder due to general medical condition, insomnia type59023.5
21.6–25.5ROR 23.6 · calibrated p 9e-4 ✓
21.4 EB05 19.9 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=579 · ♀ 100% (drug 62%) · 91% cliniciannot reported in cached trials
Folliculitis88221.7
20.3–23.2ROR 21.9 · calibrated p 0.001 ✓
19.9 EB05 18.8 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious PRR 27.4 · ♀ 100% (drug 62%) · 92% cliniciannot reported in cached trials
Helicobacter infection83420.7
19.3–22.2ROR 20.9 · calibrated p 0.002 ✓
19.1 EB05 18.0 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious PRR 23.7 · ♀ 100% (drug 62%) · 92% cliniciannot reported in cached trials
C-reactive protein abnormal50219.8
18.0–21.6ROR 19.9 · calibrated p 0.002 ✓
18.3 EB05 17.0 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=500 · ♀ 100% (drug 62%) · 94% cliniciannot reported in cached trials
Pemphigus92118.6
17.4–19.9ROR 18.8 · calibrated p 0.003 ✓
17.3 EB05 16.4 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious PRR 20.5 · ♀ 100% (drug 62%) · 94% cliniciannot reported in cached trials
Lip dry61617.2
15.8–18.6ROR 17.3 · calibrated p 0.004 ✓
16.0 EB05 15.0 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=583 · ♀ 100% (drug 62%)not reported in cached trials
Porphyria acute9216.6
13.4–20.5ROR 16.6 · calibrated p 0.005 ✓
15.5 EB05 13.0 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=92 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Hand deformity82215.6
14.5–16.7ROR 15.7 · calibrated p 0.006 ✓
14.6 EB05 13.8 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious PRR 18.7 · ♀ 100% (drug 62%) · 92% cliniciannot reported in cached trials
Retinitis10014.8
12.1–18.1ROR 14.8 · calibrated p 0.008 ✓
13.9 EB05 11.7 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=100 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Pericarditis97414.4
13.5–15.4ROR 14.6 · calibrated p 0.008 ✓
13.6 EB05 12.9 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious PRR 16.2 · ♀ 100% (drug 62%) · 93% cliniciannot reported in cached trials
Joint range of motion decreased77814.4
13.4–15.4ROR 14.5 · calibrated p 0.008 ✓
13.6 EB05 12.8 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious PRR 19.7 · ♀ 95% (drug 62%)not reported in cached trials
Bursitis65113.3
12.2–14.3ROR 13.3 · calibrated p 0.011 ✓
12.6 EB05 11.8 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious PRR 16.7 · ♀ 96% (drug 62%)not reported in cached trials
Breast cancer stage iii34013.0
11.6–14.5ROR 13.0 · calibrated p 0.013 ✓
12.3 EB05 11.2 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=340 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Autoimmune disorder49712.7
11.6–13.9ROR 12.8 · calibrated p 0.013 ✓
12.1 EB05 11.2 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious PRR 15.0 · ♀ 100% (drug 62%)not reported in cached trials
Synovitis91112.4
11.6–13.2ROR 12.5 · calibrated p 0.015 ✓
11.8 EB05 11.1 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious PRR 14.5 · ♀ 100% (drug 62%) · 94% cliniciannot reported in cached trials
Irritable bowel syndrome1,05812.1
11.4–12.9ROR 12.2 · calibrated p 0.016 ✓
11.5 EB05 11.0 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious PRR 16.5 · ♀ 97% (drug 62%)not reported in cached trials
Glossodynia (burning tongue/mouth pain)1,00811.0
10.3–11.7ROR 11.1 · calibrated p 0.023 ✓
10.5 EB05 10.0 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious PRR 16.2 · ♀ 93% (drug 62%)not reported in cached trials
Wound infection47410.6
9.7–11.6ROR 10.6 · calibrated p 0.026 ✓
10.1 EB05 9.4 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious PRR 12.6 · ♀ 100% (drug 62%)not reported in cached trials
Pustular psoriasis14810.4
8.8–12.3ROR 10.4 · calibrated p 0.029 ✓
9.9 EB05 8.6 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=142 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Blepharospasm26310.3
9.1–11.6ROR 10.3 · calibrated p 0.030 ✓
9.8 EB05 8.8 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=242 · ♀ 100% (drug 62%)not reported in cached trials
Eyelid pain769.5
7.5–11.9ROR 9.5 · calibrated p 0.041 ✓
8.9 EB05 7.3 · IC025 +2.7
3/3 methods agree
Not in label — unassessed100% consumernot reported in cached trials
Drug tolerance decreased1089.3
7.7–11.3ROR 9.3 · calibrated p 0.043 ✓
8.8 EB05 7.5 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=101 · ♀ 100% (drug 62%) · 100% cliniciannot reported in cached trials
Fibromyalgia9299.2
8.7–9.9ROR 9.3 · calibrated p 0.041 ✓
8.9 EB05 8.4 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious PRR 12.9 · ♀ 98% (drug 62%)not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Tendon disorder4793.02.7–3.2signal
Depression2,6602.22.1–2.3signal
Fall / fracture3,1581.91.9–2.0raised
Hyperglycaemia / diabetes2,7941.91.8–2.0raised
Serious infection5,5531.71.6–1.7raised
Gi bleeding1,2921.71.6–1.7raised
Liver injury2,0871.61.6–1.7raised
Interstitial lung disease6131.51.4–1.6raised
Opportunistic infection8261.41.3–1.5raised
Arrhythmia / qt1,1731.41.3–1.5raised
Anaemia1,8091.41.3–1.5raised
Venous thromboembolism1,2761.41.3–1.5raised
Pancreatitis4721.41.2–1.5raised
Kidney injury2,2701.21.1–1.2raised
Hyponatraemia3871.11.0–1.2raised
Thrombocytopenia9911.11.0–1.1no difference

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Fish Oil as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Fatigue (tiredness)8,3582.5
2.5–2.6ROR 2.7 · calibrated p 0.739
2.5 EB05 2.5 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.3 · serious PRR 3.1not reported in cached trials
Drug ineffective (drug did not work)6,2121.1
1.1–1.1ROR 1.1 · calibrated p 0.378
1.1 EB05 1.1 · IC025 +0.1Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.6not reported in cached trials
Diarrhoea (diarrhea)6,0952.2
2.2–2.3ROR 2.3 · calibrated p 0.898
2.2 EB05 2.2 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.0 · serious PRR 2.6NCT01351805: 2781/6,463 (43.0%) on Fish Oil; 2730/6,464 (42.2%) control
Nausea6,0771.8
1.8–1.8ROR 1.9 · calibrated p 0.866
1.8 EB05 1.8 · IC025 +0.8Not in label — unassessedage-adj. PRR 1.7 · serious PRR 2.3NCT01351805: 1748/6,463 (27.0%) on Fish Oil; 1771/6,464 (27.4%) control
Headache5,7922.2
2.1–2.2ROR 2.2 · calibrated p 0.927
2.2 EB05 2.1 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.1 · serious PRR 2.8not reported in cached trials
Pain5,4392.1
2.0–2.1ROR 2.1 · calibrated p 0.982
2.1 EB05 2.0 · IC025 +1.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.4 · serious PRR 2.5NCT01351805: 2439/6,463 (37.7%) on Fish Oil; 2421/6,464 (37.5%) control
Dizziness4,8142.3
2.2–2.3ROR 2.3 · calibrated p 0.884
2.3 EB05 2.2 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.1 · serious PRR 2.7not reported in cached trials
Arthralgia (joint pain)4,6562.6
2.6–2.7ROR 2.7 · calibrated p 0.721
2.6 EB05 2.6 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.6 · serious PRR 3.6not reported in cached trials
Pruritus (itching)4,3832.7
2.6–2.8ROR 2.8 · calibrated p 0.690
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.2 · serious PRR 3.3not reported in cached trials
Dyspnoea (shortness of breath)4,3821.8
1.8–1.9ROR 1.9 · calibrated p 0.862
1.8 EB05 1.8 · IC025 +0.8Not in label — unassessedage-adj. PRR 1.6 · serious PRR 2.1not reported in cached trials
Asthenia (weakness)4,1362.6
2.5–2.7ROR 2.7 · calibrated p 0.748
2.6 EB05 2.5 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.2 · serious PRR 3.1not reported in cached trials
Rash3,9072.1
2.0–2.2ROR 2.2 · calibrated p 0.970
2.1 EB05 2.0 · IC025 +1.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 3.2NCT01351805: 1629/6,463 (25.2%) on Fish Oil; 1639/6,464 (25.4%) control
Off label use (used outside approved label)3,8361.0
1.0–1.1ROR 1.0 · calibrated p 0.328
1.0 EB05 1.0 · IC025 -0.0
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 1.1 · serious PRR 1.3not reported in cached trials
Pain in extremity3,3602.7
2.6–2.8ROR 2.7 · calibrated p 0.717
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.5 · serious PRR 3.4not reported in cached trials
Vomiting3,3541.7
1.6–1.7ROR 1.7 · calibrated p 0.769
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 2.2not reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Fish Oil?

In FDA FAERS, the most frequently co-reported reaction terms for Fish Oil are fatigue, diarrhoea, nausea, headache, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Fish Oil have an FDA boxed warning?

No. The FDA label retrieved for Fish Oil has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Fish Oil causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.